LOGIN
Kunxian capsules yields short-term clinical efficacy vs placebo for ankylosing spondylitis
February 2017
Kunxian capsules yields short-term clinical efficacy vs placebo for ankylosing spondylitis
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial
Trials. 2016 Jul 22;17(1):337Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
80 patients with ankylosing spondylitis were randomized to receive a Chinese patent medicine, 0.6g Kunxian, or a placebo drug, 3 times daily for 12 weeks. The purpose of this study was to determine the efficacy of Kunxian, measured using the Assessment of SpondyloArthritis international Society (ASAS) 20 response rate. Other outcomes included ASAS 40, Bath Ankylosing Spondylitis Disease Activity I...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.